Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 1.332
Filtrar
1.
AAPS PharmSciTech ; 25(5): 90, 2024 Apr 22.
Artigo em Inglês | MEDLINE | ID: mdl-38649513

RESUMO

To formulate and optimize Ozenoxacin nano-emulsion using Quality by Design (QbD) concept by means of Box-Behnken Design (BBD) and converting it to a gel to form Ozenoxacin nano-emulgel followed by physico-chemical, in-vitro, ex-vivo and in-vivo evaluation. This study demonstrates the application of QbD methodology for the development and optimization of an effective topical nanoemulgel formulation for the treatment of Impetigo focusing on the selection of appropriate excipients, optimization of formulation and process variables, and characterization of critical quality attributes. BBD was used to study the effect of "% of oil, % of Smix and homogenization speed" on critical quality attributes "globule size and % entrapment efficiency" for the optimisation of Ozenoxacin Nano-emulsion. Ozenoxacin loaded nano-emulgel was characterized for "description, identification, pH, specific gravity, amplitude sweep, viscosity, assay, organic impurities, antimicrobial effectiveness testing, in-vitro release testing, ex-vivo permeation testing, skin retention and in-vivo anti-bacterial activity". In-vitro release and ex-vivo permeation, skin retention and in-vivo anti-bacterial activity were found to be significantly (p < 0.01) higher for the nano-emulgel formulation compared to the innovator formulation (OZANEX™). Antimicrobial effectiveness testing was performed and found that even at 70% label claim of benzoic acid is effective to inhibit microbial growth in the drug product. The systematic application of QbD principles facilitated the successful development and optimization of a Ozenoxacin Nano-Emulsion. Optimised Ozenoxacin Nano-Emulgel can be considered as an effective alternative and found to be stable at least for 6 months at 40 °C / 75% RH and 30 °C / 75% RH.


Assuntos
Antibacterianos , Emulsões , Impetigo , Quinolonas , Animais , Impetigo/tratamento farmacológico , Camundongos , Quinolonas/administração & dosagem , Quinolonas/química , Quinolonas/farmacologia , Quinolonas/farmacocinética , Antibacterianos/administração & dosagem , Antibacterianos/farmacologia , Antibacterianos/química , Emulsões/química , Nanopartículas/química , Géis/química , Química Farmacêutica/métodos , Modelos Animais de Doenças , Aminopiridinas/administração & dosagem , Aminopiridinas/farmacologia , Aminopiridinas/química , Aminopiridinas/farmacocinética , Excipientes/química , Pele/efeitos dos fármacos , Pele/metabolismo , Testes de Sensibilidade Microbiana/métodos , Absorção Cutânea/efeitos dos fármacos , Administração Tópica , Viscosidade , Composição de Medicamentos/métodos
2.
BMC Infect Dis ; 24(1): 349, 2024 Mar 26.
Artigo em Inglês | MEDLINE | ID: mdl-38528449

RESUMO

INTRODUCTION: Skin diseases such as impetigo pose a significant public health challenge in low resource settings. Despite this, there is a dearth of epidemiological data on the prevalence of this condition in Ghana. METHODS: We conducted a cross sectional study in three settings in Ghana: community members in East Mamprusi district in the North East region, a secondary school in Sekyere East district, and inmates of the Kumasi central prisons both in the Ashanti region. Following a period of training, we performed a standardised skin examination on each participant to assess for scabies and impetigo. We calculated the prevalence of each skin condition and investigated determinants of impetigo. RESULTS/ FINDINGS: Of the 1327 participants [males 64.1% and median age 22 (16-29) years], 746 (56.2%) had scabies and 186 (14%) had impetigo which was usually very mild or mild in severity. Most participants with impetigo also had scabies (161/186, 86.6%). Having an itch [RR 6.05 (95% CI 2.53-14.47)], presence of scabies burrows [RR 1.99 (95% CI 1.54-2.59)], clinical scabies [RR 3.15 (2.11-4.72)] or being in preschool [RR 4.56 (1.78-11.67)] increased the risk for impetigo. A combination of the presence of clinical scabies, age, sex and itch most accurately predicted the odds of having impetigo. CONCLUSIONS: There is substantial burden of impetigo and scabies in Ghana. There is a need to institute measures to improve detection and control of these common dermatoses as part of Universal Health Coverage package to reduce the scourge of the diseases in this setting.


Assuntos
Impetigo , Escabiose , Pré-Escolar , Masculino , Humanos , Adulto Jovem , Adulto , Impetigo/epidemiologia , Estudos Transversais , Escabiose/epidemiologia , Prevalência , Gana/epidemiologia
4.
J Int Med Res ; 51(12): 3000605231217950, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-38102997

RESUMO

Impetigo herpetiformis is a rare skin disease that most often occurs in the third trimester of pregnancy. It is currently considered as a form of generalized pustular psoriasis and the typical skin lesions comprise small sterile pustules. Here, a case of impetigo herpetiformis in the second trimester of pregnancy after 7 weeks of hydroxychloroquine administration for suspected Sjogren's syndrome is reported. Treatment with anti-infective, anti-inflammatory and immunosuppressive medication did not improve the patient's condition. Following delivery of a live male by emergency caesarean section at 29 weeks' gestation, the rash was reported to be completely resolved by 3 months postpartum. Previously published cases of impetigo herpetiformis in the second trimester of pregnancy that were retrieved from a search of the PubMed database are also reviewed and discussed.


Assuntos
Dermatite Herpetiforme , Exantema , Impetigo , Complicações Infecciosas na Gravidez , Psoríase , Feminino , Humanos , Gravidez , Cesárea , Dermatite Herpetiforme/diagnóstico , Dermatite Herpetiforme/tratamento farmacológico , Dermatite Herpetiforme/patologia , Impetigo/diagnóstico , Impetigo/tratamento farmacológico , Segundo Trimestre da Gravidez , Psoríase/patologia
5.
Medicina (Kaunas) ; 59(11)2023 Oct 27.
Artigo em Inglês | MEDLINE | ID: mdl-38003954

RESUMO

Background and Objectives: Dermatological disorders are highly prevalent among children in Pakistan. The present cross-sectional study aims to identify the spectrum of dermatological conditions among children and adolescents in Pakistan. Materials and Methods: A total of 582 patients (50.9% males; 49.1% females) were included in the study based on their age (5.7 ± 4.1 years), dermatological condition, and epidemiology. The youngest patient was aged ten days, whereas the eldest was seventeen. Age criteria were further stratified into three categories: infants and toddlers (≤5 years), children (≥5 to <12 years), and adolescents (≥12 to <18 years). Amongst them, the majority was from Punjab (81.6%), while the other regions included were Azad Jammu and Kashmir (14.4%), Islamabad (3.3%), and Khyber Pakhtunkhwa (0.7%). Results: Scabies was the highest reported skin condition with 281 (45.55%) patients, followed by 114 (19.6%) with eczema, 60 (10.3%) with dermatitis, 33 (5.7%) with tinea capitis, 17 (2.9%) with tinea corporis, 16 (2.7%) with impetigo, and 15 (2.6%) with folliculitis. Other conditions include urticaria, burns, infections, pediculosis, tinea inguinalis, tinea faciei, nappy rashes, alopecia, warts, tinea incognito, tinea cruris, and acne vulgaris. The chi-squared test showed a high prevalence of tinea corporis and acne among adolescents (12-17 years), whereas eczema, dermatitis, and impetigo were more prevalent among infants and toddlers. Conclusions: Pets or livestock and poor hygiene were found to be highly reported risk factors for many dermatological conditions like scabies and fungal infections. Dermatological conditions are common in younger individuals, but unfortunately, many children do not receive the desired medical assistance.


Assuntos
Eczema , Impetigo , Escabiose , Tinha , Masculino , Lactente , Feminino , Humanos , Adolescente , Estudos Transversais , Paquistão/epidemiologia , Tinha/epidemiologia , Tinha/microbiologia
6.
PLoS One ; 18(11): e0288016, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38033025

RESUMO

BACKGROUND: Streptoccocal A (Strep A, GAS) infections in Australia are responsible for significant morbidity and mortality through both invasive (iGAS) and post-streptococcal (postGAS) diseases as well as preceding superficial (sGAS) skin and throat infection. The burden of iGAS and postGAS are addressed in some jurisdictions by mandatory notification systems; in contrast, the burden of preceding sGAS has no reporting structure, and is less well defined. This review provides valuable, contemporaneous evidence on the epidemiology of sGAS presentations in Australia, informing preventative health projects such as a Streptococcal A vaccine and standardisation of primary care notification. METHODS AND FINDINGS: MEDLINE, Scopus, EMBASE, Web of Science, Global Health, Cochrane, CINAHL databases and the grey literature were searched for studies from an Australian setting relating to the epidemiology of sGAS infections between 1970 and 2020 inclusive. Extracted data were pooled for relevant population and subgroup analysis. From 5157 titles in the databases combined with 186 grey literature reports and following removal of duplicates, 4889 articles underwent preliminary title screening. The abstract of 519 articles were reviewed with 162 articles identified for full text review, and 38 articles identified for inclusion. The majority of data was collected for impetigo in Aboriginal and Torres Strait Islander populations, remote communities, and in the Northern Territory, Australia. A paucity of data was noted for Aboriginal and Torres Strait Islander people living in urban centres or with pharyngitis. Prevalence estimates have not significantly changed over time. Community estimates of impetigo point prevalence ranged from 5.5-66.1%, with a pooled prevalence of 27.9% [95% CI: 20.0-36.5%]. All studies excepting one included >80% Aboriginal and Torres Strait Islander people and all excepting two were in remote or very remote settings. Observed prevalence of impetigo as diagnosed in healthcare encounters was lower, with a pooled estimate of 10.6% [95% CI: 3.1-21.8%], and a range of 0.1-50.0%. Community prevalence estimates for pharyngitis ranged from 0.2-39.4%, with a pooled estimate of 12.5% [95% CI: 3.5-25.9%], higher than the prevalence of pharyngitis in healthcare encounters; ranging from 1.0-5.0%, and a pooled estimate of 2.0% [95% CI: 1.3-2.8%]. The review was limited by heterogeneity in study design and lack of comparator studies for some populations. CONCLUSIONS: Superficial Streptococcal A infections contribute to an inequitable burden of disease in Australia and persists despite public health interventions. The burden in community studies is generally higher than in health-services settings, suggesting under-recognition, possible normalisation and missed opportunities for treatment to prevent postGAS. The available, reported epidemiology is heterogeneous. Standardised nation-wide notification for sGAS disease surveillance must be considered in combination with the development of a Communicable Diseases Network of Australia (CDNA) Series of National Guideline (SoNG), to accurately define and address disease burden across populations in Australia. TRIAL REGISTRATION: This review is registered with PROSPERO. Registration number: CRD42019140440.


Assuntos
Serviços de Saúde do Indígena , Impetigo , Faringite , Humanos , Povos Aborígenes Australianos e Ilhéus do Estreito de Torres , Impetigo/epidemiologia , Impetigo/microbiologia , Northern Territory , Faringite/epidemiologia , Faringite/microbiologia , Streptococcus
7.
J Paediatr Child Health ; 59(12): 1296-1303, 2023 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-37920140

RESUMO

AIM: Here, we present results of a survey of scabies prevalence in childcare centres and primary schools in Auckland. METHODS: Children whose parents agreed to take part in participating centres in the Auckland region were examined for scabies by general practitioners and given questionnaires of relevant symptoms. Diagnoses of clinical or suspected scabies were made according to the International Alliance for the Control of Scabies (IACS) criteria. The survey was a stratified random sample of schools and early childcare centres. A quantitative polymerase chain reaction (PCR) test was also used to complement the IACS criteria. RESULTS: A total of 181 children were examined, with 145 children with history information, 16 of whom (11.0%) met the criteria for 'clinical' or 'suspected' scabies. Weighted analysis, accounting for the survey design, indicated that the prevalence of scabies in early childcare centres was 13.2% (95% CI: 4.3 to 22.1), with no school-aged children fulfilling these criteria. A higher proportion had clinical signs of scabies with 23 (12.7%) having typical scabies lesions and a further 43 (23.8%) had atypical lesions. A total of 64 PCR tests were taken and 15 (23%) were positive. None of these cases were receiving treatment for scabies. Five were undergoing topical skin treatment: three with topical steroid and two with calamine lotion. CONCLUSIONS: The prevalence of children with scabies is high in early childcare centres in Auckland. Misdiagnosis is suggested by several PCR positive cases being treated by topical agents used to treat other skin conditions.


Assuntos
Impetigo , Escabiose , Criança , Humanos , Escabiose/diagnóstico , Escabiose/epidemiologia , Impetigo/diagnóstico , Impetigo/tratamento farmacológico , Impetigo/epidemiologia , Prevalência , Instituições Acadêmicas , Inquéritos e Questionários , Erros de Diagnóstico
8.
J Med Chem ; 66(20): 14263-14277, 2023 10 26.
Artigo em Inglês | MEDLINE | ID: mdl-37796116

RESUMO

Thiopeptides exhibit potent antimicrobial activity against Gram-positive pathogens by inhibiting bacterial protein synthesis. Micrococcins are among the structurally simpler thiopeptides, but they have not been exploited in detail. This research involved a computational simulation of micrococcin P2 (MP2) docking in parallel with the structure-activity relationship (SAR) studied. The incorporation of particular nitrogen heterocycles in the side chain of MP2 enhances the antimicrobial activity. Micrococcin analogues 6c and 6d thus proved to be more effective against impetigo and C. difficile infection (CDI), respectively, as compared to current first-line treatments. Compound 6c also showed a shorter treatment period than that of a first-line treatment for impetigo. This may be attributed to its ability to downregulate pro-inflammatory cytokines. Compound 6d had no observed recurrence for C. difficile and exerted a minimal impact on the beneficial gut microbiome. Their pharmacokinetic properties and low toxicity profile make these compounds ideal candidates for the treatment of impetigo and CDI and validate their involvement in preclinical development.


Assuntos
Clostridioides difficile , Impetigo , Humanos , Antibacterianos/farmacologia , Antibacterianos/química
9.
Eur Rev Med Pharmacol Sci ; 27(19): 9273-9278, 2023 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37843341

RESUMO

OBJECTIVE: Ozenoxacin is a new antibiotic used to treat non-bullous impetigo. The aim of this study is to evaluate the microbiological and clinical efficacy of topical ozenoxacin 1% cream after 5-day twice-daily treatment, in pediatric patients with impetigo. PATIENTS AND METHODS: This observational and prospective study included patients aged 6 months to 18 years, with non-bullous impetigo. Efficacy was measured using the Skin Infection Rating Scale (SIRS) and microbiological culture at the first visit (T0), at the second visit after 72 hours (T1) and after 5 days (T2). Safety and tolerability were also evaluated. RESULTS: A total of 50 patients was enrolled. A reduction of SIRS score >10% after 72 hours of treatment was noticed in all patients, while a complete reduction was assessed after 5 days in all the population. Microbiologic success rates for ozenoxacin at T1 was 92% (four patients had original pathogens in the specimen culture from the skin area), whereas at T2, it was 100%. CONCLUSIONS: Topical ozenoxacin has strong efficacy in treating impetigo in pediatric patients. Ozenoxacin's clinical and microbiological rapid onset of response led to consider this antibiotic a novel efficacy option for the treatment of impetigo.


Assuntos
Impetigo , Humanos , Criança , Impetigo/diagnóstico , Impetigo/tratamento farmacológico , Impetigo/microbiologia , Estudos Prospectivos , Antibacterianos , Síndrome de Resposta Inflamatória Sistêmica
10.
J Antimicrob Chemother ; 78(8): 2061-2065, 2023 08 02.
Artigo em Inglês | MEDLINE | ID: mdl-37358399

RESUMO

OBJECTIVES: In August 2018, a public health alert was issued in Belgium regarding clusters of impetigo cases caused by the epidemic European fusidic acid-resistant impetigo clone (EEFIC) of Staphylococcus aureus. As a result, the Belgian national reference centre (NRC) was commissioned to update the epidemiology of S. aureus causing community-onset skin and soft tissues infection (CO-SSTI) to assess the proportion of EEFIC among them. METHODS: For 1 year, Belgian clinical laboratories were asked to send their first three S. aureus isolated from CO-SSTI each month. Isolates were tested for antimicrobial susceptibility to oxacillin, mupirocin and fusidic acid. Resistant isolates were also spa typed and tested for the presence of the genes encoding the Panton-Valentine leucocidin, the toxic shock syndrome toxin and the exfoliatins A and B. MLST clonal complexes were deduced from the spa types. RESULTS: Among the 518 S. aureus strains analysed, 487 (94.0%) were susceptible to oxacillin. Of these, 79 (16.2%) were resistant to fusidic acid, of which 38 (48.1%) belonged to the EEFIC. EEFIC isolates were mostly isolated from young patients with impetigo and showed a seasonal late summer peak. CONCLUSIONS: These results suggest the persistence of EEFIC in Belgium. Furthermore, its prevalence may lead to reconsideration of the treatment guidelines for impetigo.


Assuntos
Impetigo , Staphylococcus aureus Resistente à Meticilina , Infecções Estafilocócicas , Humanos , Ácido Fusídico/farmacologia , Impetigo/epidemiologia , Impetigo/tratamento farmacológico , Staphylococcus aureus , Bélgica/epidemiologia , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Tipagem de Sequências Multilocus , Farmacorresistência Bacteriana/genética , Infecções Estafilocócicas/epidemiologia , Infecções Estafilocócicas/tratamento farmacológico , Oxacilina , Células Clonais
11.
Mil Med ; 188(5-6): e1332-e1334, 2023 05 16.
Artigo em Inglês | MEDLINE | ID: mdl-37191635

RESUMO

The differential diagnosis of vesiculobullous lesions can be intimidating to the primary care provider. While some entities such as bullous impetigo may easily be diagnosed clinically if the patient's demographics as well as the lesion morphology and distribution present classically, atypical presentations may require additional laboratory studies for confirmation. We describe a case of bullous impetigo with characteristics that clinically mimicked two rare immunobullous dermatoses. Although extensive diagnostic testing was performed, we recommend an approach for primary care providers to initiate empiric treatment while maintaining awareness of less common immunobullous entities.


Assuntos
Impetigo , Dermatopatias Vesiculobolhosas , Lesões dos Tecidos Moles , Humanos , Impetigo/diagnóstico , Impetigo/patologia , Dermatopatias Vesiculobolhosas/diagnóstico , Dermatopatias Vesiculobolhosas/patologia , Diagnóstico Diferencial
12.
Lancet Glob Health ; 11(6): e924-e932, 2023 06.
Artigo em Inglês | MEDLINE | ID: mdl-37202027

RESUMO

BACKGROUND: Integrated programmes that use combination mass drug administration (MDA) might improve control of multiple neglected tropical diseases simultaneously. We investigated the impact of Timor-Leste's national ivermectin, diethylcarbamazine citrate, and albendazole MDA, for lymphatic filariasis elimination and soil-transmitted helminth (STH) control, on scabies, impetigo, and STH infections. METHODS: We did a before-after study in six primary schools across three municipalities in Timor-Leste (urban [Dili], semi-urban [Ermera], and rural [Manufahi]) before (April 23 to May 11, 2019) and 18 months after (Nov 9 to Nov 27, 2020) MDA delivery between May 17 and June 1, 2019. Study participants included schoolchildren, as well as infants, children, and adolescents who were incidentally present at school on study days. All schoolchildren whose parents provided consent were eligible to participate in the study. Infants, children, and adolescents younger than 19 years who were not enrolled in the school but were incidentally present at schools on study days were also eligible to participate if their parents consented. Ivermectin, diethylcarbamazine citrate, and albendazole MDA was implemented nationally, with single doses of oral ivermectin (200 µg/kg), diethylcarbamazine citrate (6 mg/kg), and albendazole (400 mg) administered by the Ministry of Health. Scabies and impetigo were assessed by clinical skin examinations, and STHs using quantitative PCR. The primary (cluster-level) analysis adjusted for clustering while the secondary (individual-level) analysis adjusted for sex, age, and clustering. The primary outcomes of the study were prevalence ratios for scabies, impetigo, and STHs (Trichuris trichiura, Ascaris lumbricoides, Necator americanus, and moderate-to-heavy A lumbricoides infections) between baseline and 18 months from the cluster-level analysis. FINDINGS: At baseline, 1043 (87·7%) of 1190 children registered for the study underwent clinical assessment for scabies and impetigo. The mean age of those who completed skin examinations was 9·4 years (SD 2·4) and 514 (53·8%) of 956 were female (87 participants with missing sex data were excluded from this percentage calculation). Stool samples were received for 541 (45·5%) of 1190 children. The mean age of those for whom stool samples were received was 9·8 years (SD 2·2) and 300 (55·5%) were female. At baseline, 348 (33·4%) of 1043 participants had scabies, and 18 months after MDA, 133 (11·1%) of 1196 participants had scabies (prevalence ratio 0·38, 95% CI 0·18-0·88; p=0·020) in the cluster-level analysis. At baseline, 130 (12·5%) of 1043 participants had impetigo, compared with 27 (2·3%) of 1196 participants at follow-up (prevalence ratio 0·14, 95% CI 0·07-0·27; p<0·0001). There was a significant reduction in T trichiura prevalence from baseline (26 [4·8%] of 541 participants) to 18-month follow-up (four [0·6%] of 623 participants; prevalence ratio 0·16, 95% CI 0·04-0·66; p<0·0001). In the individual-level analysis, moderate-to-heavy A lumbricoides infections reduced from 54 (10·0%; 95% CI 0·7-19·6) of 541 participants to 28 (4·5%, 1·2-8·4) of 623 participants (relative reduction 53·6%; 95% CI 9·1-98·1; p=0·018). INTERPRETATION: Ivermectin, diethylcarbamazine citrate, and albendazole MDA was associated with substantial reductions in prevalence of scabies, impetigo, and T trichiura, and of moderate-to-heavy intensity A lumbricoides infections. Combination MDA could be used to support integrated control programmes to target multiple NTDs. FUNDING: National Health and Medical Research Council of Australia and the Department of Foreign Affairs and Trade Indo-Pacific Centre for Health Security. TRANSLATION: For the Tetum translation of the abstract see Supplementary Materials section.


Assuntos
Anti-Helmínticos , Helmintíase , Helmintos , Impetigo , Escabiose , Lactente , Animais , Adolescente , Criança , Humanos , Feminino , Masculino , Albendazol/uso terapêutico , Ivermectina/uso terapêutico , Dietilcarbamazina/uso terapêutico , Escabiose/tratamento farmacológico , Escabiose/epidemiologia , Administração Massiva de Medicamentos , Impetigo/tratamento farmacológico , Impetigo/epidemiologia , Solo/parasitologia , Prevalência , Timor-Leste/epidemiologia , Cidades , Helmintíase/tratamento farmacológico , Helmintíase/epidemiologia , Anti-Helmínticos/uso terapêutico
13.
Lancet Microbe ; 4(7): e524-e533, 2023 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-37211022

RESUMO

BACKGROUND: Streptococcus pyogenes, or group A Streptococcus (GAS), infections contribute to a high burden of disease in Aboriginal Australians, causing skin infections and immune sequelae such as rheumatic heart disease. Controlling skin infections in these populations has proven difficult, with transmission dynamics being poorly understood. We aimed to identify the relative contributions of impetigo and asymptomatic throat carriage to GAS transmission. METHODS: In this genomic analysis, we retrospectively applied whole genome sequencing to GAS isolates that were collected as part of an impetigo surveillance longitudinal household survey conducted in three remote Aboriginal communities in the Northern Territory of Australia between Aug 6, 2003, and June 22, 2005. We included GAS isolates from all throats and impetigo lesions of people living in two of the previously studied communities. We classified isolates into genomic lineages based on pairwise shared core genomes of more than 99% with five or fewer single nucleotide polymorphisms. We used a household network analysis of epidemiologically and genomically linked lineages to quantify the transmission of GAS within and between households. FINDINGS: We included 320 GAS isolates in our analysis: 203 (63%) from asymptomatic throat swabs and 117 (37%) from impetigo lesions. Among 64 genomic lineages (encompassing 39 emm types) we identified 264 transmission links (involving 93% of isolates), for which the probable source was asymptomatic throat carriage in 166 (63%) and impetigo lesions in 98 (37%). Links originating from impetigo cases were more frequent between households than within households. Households were infected with GAS for a mean of 57 days (SD 39 days), and once cleared, reinfected 62 days (SD 40 days) later. Increased household size and community presence of GAS and scabies were associated with slower clearance of GAS. INTERPRETATION: In communities with high prevalence of endemic GAS-associated skin infection, asymptomatic throat carriage is a GAS reservoir. Public health interventions such as vaccination or community infection control programmes aimed at interrupting transmission of GAS might need to include consideration of asymptomatic throat carriage. FUNDING: Australian National Health and Medical Research Council.


Assuntos
Impetigo , Dermatopatias Infecciosas , Infecções Estreptocócicas , Humanos , Impetigo/epidemiologia , Streptococcus pyogenes/genética , Estudos Retrospectivos , Faringe , Northern Territory/epidemiologia , Infecções Estreptocócicas/epidemiologia , Genômica
14.
Dermatol Online J ; 29(1)2023 Feb 15.
Artigo em Inglês | MEDLINE | ID: mdl-37040917

RESUMO

Bullous impetigo is a variant of epidermal infection by Staphylococcus aureus, representing 30% of impetigo cases. Its clinical appearance may mimic certain autoimmune blistering dermatoses and other cutaneous infections, sometimes necessitating careful evaluation. Herein we present a patient with bullous impetigo in a striking and characteristic appearance and briefly overview the approach to diagnosis, treatment, and prevention.


Assuntos
Doenças Autoimunes , Impetigo , Dermatopatias , Infecções Estafilocócicas , Masculino , Humanos , Impetigo/diagnóstico , Vesícula , Abdome
15.
PeerJ ; 11: e14945, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-36935916

RESUMO

Introduction: Group A Streptococcus (GAS) causes pharyngitis (sore throat) and impetigo (skin sores) GAS pharyngitis triggers rheumatic fever (RF) with epidemiological evidence supporting that GAS impetigo may also trigger RF in Australian Aboriginal children. Understanding the concurrent burden of these superficial GAS infections is critical to RF prevention. This pilot study aimed to trial tools for concurrent surveillance of sore throats and skins sore for contemporary studies of RF pathogenesis including development of a sore throat checklist for Aboriginal families and pharynx photography. Methods: Yarning circle conversations and semi-structured interviews were performed with Aboriginal caregivers and used to develop the language and composition of a sore throat checklist. The sore throat story checklist was combined with established methods of GAS pharyngitis and impetigo surveillance (examination, bacteriological culture, rapid antigen detection and serological tests) and new technologies (photography) and used for a pilot cross-sectional surveillance study of Aboriginal children attending their health clinic for a routine appointment. Feasibility, acceptability, and study costs were compiled. Results: Ten Aboriginal caregivers participated in the sore-throat yarning circles; a checklist was derived from predominant symptoms and their common descriptors. Over two days, 21 Aboriginal children were approached for the pilot surveillance study, of whom 17 were recruited; median age was 9 years [IQR 5.5-13.5], 65% were female. One child declined throat swabbing and three declined finger pricks; all other surveillance elements were completed by each child indicating high acceptability of surveillance assessments. Mean time for screening assessment was 19 minutes per child. Transport of clinical specimens enabled gold standard microbiological and serological testing for GAS. Retrospective examination of sore throat photography concorded with assessments performed on the day. Conclusion: Yarning circle conversations were effective in deriving culturally appropriate sore throat questionnaires for GAS pharyngitis surveillance. New and established tools were feasible, practical and acceptable to participants and enable surveillance to determine the burden of superficial GAS infections in communities at high risk of RF. Surveillance of GAS pharyngitis and impetgio in remote Australia informs primary RF prevention with potential global translation.


Assuntos
Impetigo , Faringite , Febre Reumática , Infecções Estreptocócicas , Criança , Humanos , Feminino , Pré-Escolar , Adolescente , Masculino , Projetos Piloto , Estudos Retrospectivos , Estudos Transversais , Austrália/epidemiologia , Streptococcus pyogenes , Febre Reumática/epidemiologia , Infecções Estreptocócicas/diagnóstico , Faringite/diagnóstico
16.
PLoS Negl Trop Dis ; 17(3): e0011207, 2023 03.
Artigo em Inglês | MEDLINE | ID: mdl-36930667

RESUMO

BACKGROUND: Mass drug administration (MDA) based on two doses of ivermectin, one week apart, substantially reduces prevalence of both scabies and impetigo. The Regimens of Ivermectin for Scabies Elimination (RISE) trial assessed whether one-dose ivermectin-based MDA would be as effective. METHODS: RISE was a cluster-randomised trial in Solomon Islands. We assigned 20 villages in a 1:1 ratio to one- or two-dose ivermectin-based MDA. We planned to test whether the impact of one dose on scabies prevalence at 12 and 24 months was non-inferior to two, at a 5% non-inferiority margin. RESULTS: We deferred endpoint assessment to 21 months due to COVID-19. We enrolled 5239 participants in 20 villages at baseline and 3369 at 21 months from an estimated population of 5500. At baseline scabies prevalence was similar in the two arms (one-dose 17·2%; two-dose 13·2%). At 21 months, there was no reduction in scabies prevalence (one-dose 18·7%; two-dose 13·4%), and the confidence interval around the difference included values substantially greater than 5%. There was however a reduction in prevalence among those who had been present at the baseline assessment (one-dose 15·9%; two-dose 10·8%). Additionally, we found a reduction in both scabies severity and impetigo prevalence in both arms, to a similar degree. CONCLUSIONS: There was no indication of an overall decline in scabies prevalence in either arm. The reduction in scabies prevalence in those present at baseline suggests that the unexpectedly high influx of people into the trial villages, likely related to the COVID-19 pandemic, may have compromised the effectiveness of the MDA. Despite the lack of effect there are important lessons to be learnt from this trial about conducting MDA for scabies in high prevalence settings. TRIAL REGISTRATION: Registered with Australian New Zealand Clinical Trials Registry ACTRN12618001086257.


Assuntos
COVID-19 , Impetigo , Escabiose , Humanos , Ivermectina/uso terapêutico , Escabiose/tratamento farmacológico , Escabiose/epidemiologia , Escabiose/prevenção & controle , Administração Massiva de Medicamentos , Impetigo/tratamento farmacológico , Impetigo/epidemiologia , Impetigo/prevenção & controle , Pandemias , Austrália , COVID-19/epidemiologia
17.
J Dermatol ; 50(1): 3-11, 2023 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-36152301

RESUMO

The Japanese Society for Psoriasis Research (JSPR) has been conducting annual epidemiological surveys of patients with pustular psoriasis in Japan since 2017. This study aimed to conduct a recent epidemiological analysis of patients with pustular psoriasis who were enrolled in the JSPR from 2017 to 2020. A total of 291 patients from 131 medical institutions were enrolled, of which 47.4% (138 cases) were males and 52.6% (153 cases) were females. The mean ± standard deviation (SD) age of the patients was 57.4 ± 20.3 years (males, 61.2 ± 17.3 years; females, 54.1 ± 22.1 years). The mean ± SD age of the patients at disease onset was 48.5 ± 22.5 years (males, 50.8 ± 20.6 years; females, 46.4 ± 24.0 years). The types of pustular psoriasis observed included the von Zumbusch type (59.8%), annular pustular psoriasis (8.2%), impetigo herpetiformis (6.5%), and acrodermatitis continua of Hallopeau (4.8%), of which, the majority of the patients with impetigo herpetiformis were female. Among the patients, 58.4% were treated with oral medications and 44.0% were treated with biologics. The most common oral medication prescribed was etretinate (52.4%), followed by corticosteroids (24.7%) and cyclosporin (22.9%). The most common biologics used were IL-17 inhibitors (ixekizumab [28.1%] and secukinumab [22.7%]), followed by tumor necrosis factor (TNF) inhibitors (infliximab [15.6%]) and IL-23 inhibitors (guselkumab [14.8%] and risankizumab [10.2%]). This survey thus provides new and significant information regarding the recent perspective of pustular psoriasis, such as patient characteristics and treatment trends, in Japan.


Assuntos
Produtos Biológicos , Etretinato , Exantema , Impetigo , Psoríase , Dermatopatias Vesiculobolhosas , Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Impetigo/tratamento farmacológico , População do Leste Asiático , Psoríase/tratamento farmacológico , Etretinato/uso terapêutico , Produtos Biológicos/uso terapêutico , Exantema/tratamento farmacológico , Dermatopatias Vesiculobolhosas/tratamento farmacológico
18.
Mol Pharm ; 20(2): 1382-1393, 2023 02 06.
Artigo em Inglês | MEDLINE | ID: mdl-36583939

RESUMO

The study aimed to improve the treatment of impetigo with naturally occurring quercetin and its copper-quercetin (Cu-Q) complex by preparing sustained-release (SR) nanoparticles of polycaprolactone (PCL). The solvent evaporation method was used for the copper-quercetin (Cu-Q) complex formation, and their PCL nanoparticles (PCL-NPs, Q-PCL-NPs, and Cu-Q-PCL-NPs) were prepared by the high-pressure homogenization method. Synthesis of nanoparticles was confirmed by their physicochemical and antibacterial properties of quercetin against Gram-positive as well as Gram-negative bacteria. The percentage loading efficiency of quercetin and release in 100 mM of phosphate buffer pH 7.4 and 5.5 at 37 °C was found to be more than 90% after 24 h with the zero-order release pattern. Minimum inhibitory concentration of nanoparticles was found to increase threefold in the case of Cu-Q-PCL-NPs may be due to the synergistic antibacterial behavior. Scanning electron microscopy showed spherical nanoparticles, and surface roughness was confirmed by atomic force microscopy analysis. Fortunately, no sign of irritation on rat skin even at 3%, was seen. In vitro antioxidant assay by 2,2-diphenyl-1-picrylhydrazyl reduction was found to be ≤80 ± 0.02% which confirmed their scavenging activity. Interestingly, for the ex vivo study, the tape-stripping model was applied against Staphylococcus aureus containing rats and showed the formation of the epidermal layer within 4-5 days. Confirmation of antibacterial activity of pure quercetin, from Cu-Q complex, and their SR release from Q-PCL-NPs and Cu-Q-PCL-NPs was considered an effective tool for the treatment of skin diseases and can be used as an alternative of already resistant ciprofloxacin in impetigo.


Assuntos
Impetigo , Nanopartículas , Ratos , Animais , Quercetina/farmacologia , Quercetina/uso terapêutico , Quercetina/química , Cobre/química , Preparações de Ação Retardada , Nanopartículas/química , Antibacterianos/farmacologia , Antibacterianos/química
19.
J Ayub Med Coll Abbottabad ; 35(3): 497-499, 2023.
Artigo em Inglês | MEDLINE | ID: mdl-38404102

RESUMO

We present the case of a 30-year-old woman who presented with 8-month history of intermittent fever, joint pains with morning stiffness, recurrent oral ulcers, photosensitivity, weight loss and hair fall. For the last 2 months, she had developed a dry cough with progressive shortening of breath. On examination, a cachexic lady with malar hyperpigmentation, alopecia, pallor, nail dystrophy and erythema over her hands and feet were noted. There were multiple punched-out skin ulcers of variable size over legs, arms and abdomen usually round in shape with well-defined even wound margins and scant serous discharge. Musculoskeletal examination revealed synovitis of both elbows and a few metacarpophalangeal and proximal interphalangeal joints. Chest X-ray and HRCT showed bilateral ground-glass opacification. Anti-Nuclear Antibody (ANA) was positive, 1:320, homogenous nuclear pattern. Anti-Ro antibody was highly positive and serum complement (C3, C4) levels were reduced. She was diagnosed with Lupus Vasculitis and started on steroids, mycophenolate mofetil and hydroxychloroquine.


Assuntos
Oftalmopatias , Impetigo , Humanos , Feminino , Adulto , Celulite (Flegmão) , Paquistão , Ácido Micofenólico
20.
Rev. odontopediatr. latinoam ; 13: 422522, 2023. ilus, tab
Artigo em Espanhol | LILACS, COLNAL | ID: biblio-1435323

RESUMO

Existen diversos diagnósticos clínicos diferenciales de lesiones infectocontagiosas peribucales en la infancia, siendo las más frecuentes: herpes labial, queilitis angular (queilocandidiasis) e impétigo, esta última es una infección bacteriana prevalente en población infantil, afectando la región labial y peribucal, cuyo diagnóstico está principalmente basado en los hallazgos clínicos y en el análisis minucioso de la anamnesis. Objetivo: Presentar dos casos clínicos de impétigo ampolloso en pacientes pediátricos, destacando sus características, comparándolas y contrastándolas con sus principales diagnósticos diferenciales. Reporte de casos. Se presentan dos casos de pacientes masculinos de 10 años (hermanos gemelos) con antecedentes de secuencia de Pierre Robin, los cuales acudieron a la clínica de Odontopediatría de la ENES, UNAM, unidad León, presentando múltiples lesiones ulcerativas, localizadas área peribucal, refiriendo dos semanas de evolución. Diagnóstico. Se estableció el diagnóstico clínico de: impétigo ampolloso, para ambos pacientes. Plan de tratamiento. Se indicaron medidas estrictas de higiene general y en las zonas afectadas, eliminando también cualquier objeto que actuara como fómite, evitando compartir productos de aseo personal, además, se indicó la aplicación de mupirocina en crema al 2%, llevándose a cabo el seguimiento a los 14 y 30 días hasta la curación completa. Conclusiones. El impétigo peribucal es frecuentemente confundido con otras infecciones presentes en esa localización con manifestaciones clínicas semejantes en algunos casos suele ser tratado erróneamente. Por lo que se destaca la importancia de realizar un adecuado interrogatorio, una exploración clínica concienzuda y realizar un análisis diferencial clínico en este tipo de lesiones.


Existem vários diagnósticos clínicos diferenciais de lesões periorais infecciosas na infância, sendo os mais frequentes: herpes labial, queilite angular (queilocandidíase) e impetigo, sendo este último uma infecção bacteriana prevalente em crianças, acometendo a região labial e perioral, cujo diagnóstico é principalmente baseado em achados clínicos e na análise cuidadosa da anamnese. Objetivo: Apresentar dois casos clínicos de impetigo bolhoso em pacientes pediátricos, destacando as características, comparando-os e contrastando-os com os principais diagnósticos diferenciais. Relato de caso. Apresentam-se dois casos de pacientes do sexo masculino (irmãos gêmeos) de 10 anos de idade com histórico de sequência de Pierre Robin, que compareceram à clínica de Odontopediatria da ENES, UNAM, unidade León, apresentando múltiplas lesões ulcerativas, localizadas na zona perioral, referindo duas semanas de evolução. Diagnóstico. Estabeleceu-se o diagnóstico clínico de: impetigo bolhoso para ambos os pacientes. Plano de tratamento. Foram indicadas medidas rigorosas de higiene geral e nas áreas afetadas, eliminando também qualquer objeto que atuasse como fômite, evitando o compartilhamento de produtos de higiene pessoal, além disso, foi indicada a aplicação de creme de mupirocina 2%, realizando o acompanhamento em 14 e 30 dias até a cura completa. Conclusões. Frequentemente, o impetigo perioral é confundido com outras infecções presentes nessa localização com manifestações clínicas semelhantes e, em alguns casos, geralmente é tratado erroneamente. Destaca-se, portanto, a importância de se realizar um interrogatório adequado, um exame clínico minucioso e uma análise clínica diferencial neste tipo de lesões


There are several differential clinical diagnoses of infectious perioral lesions in childhood, the most frequent being: herpes labialis, angular cheilitis (cheilocandidiasis) and impetigo, the latter being a bacterial infection prevalent in children, with rupture of the labial and perioral region, whose diagnosis is mainly based on clinical findings and careful analysis of the anamnesis. Objective: To present two clinical cases of bullous impetigo in pediatric patients, highlighting their characteristics, comparing, and contrasting them with their main differential diagnoses. Case report. We present two cases of 10-year-old male patients (twin brothers) with a history of Pierre Robin sequence, who attended the Pediatric Dentistry clinic of the ENES, UNAM, León unit, presenting multiple ulcerative lesions, located in the perioral area, referring two weeks of evolution. Diagnosis. The clinical diagnosis of: bullous impetigo is established for both patients. Treatment plan. Strict general hygiene measures were indicated and in the affected areas, also eliminating any object that acted as a fomite, preventing the sharing of personal hygiene products, in addition, the application of mupirocin cream at 2% was shown, carrying out the monitoring of the 14 and 30 days until complete healing. Conclusions. Perioral impetigo is frequently confused with other infections present in that location with similar clinical manifestations. In some cases, it is usually treated incorrectly. Therefore, the importance of carrying out an adequate interrogation, a thorough clinical examination and performing a clinical differential analysis in this type of injury is highlighted.


Assuntos
Humanos , Masculino , Criança , Queilite , Impetigo , Infecções Bacterianas
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...